In cancer, aberrantly active STAT3 drives oncogenic programs, promoting cell-cycle progression, uncontrolled proliferation, resistance to apoptosis, and tumor neoangiogenesis (Hu et al., 2024). Here, STAT3 is linked to neoplasm.